To print: Select File and then Print from your browser's menu

Title: Olmesartan Improves Insulin Resistance in Chronic Kidney Disease Patients: Presented at ASN

"Olmesartan Improves Insulin Resistance in Chronic Kidney Disease Patients: Presented at ASN"

By Maria Bishop PHILADELPHIA, PA -- November 15, 2005 -- Olmesartan, an angiotensin receptor blocker, has been demonstrated to improve the insulin resistance and metabolic syndrome prevalent in patients with chronic kidney disease. Researchers reported the findings here on November 12[^th at the 38^th Annual Meeting and Scientific Exposition of the American Society of Nephrology (ASN).

Researchers led by José Luño, MD, Nephrology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain, administered olmesartan at a 40-mg dose for 16 weeks to 52 patients with stages 3 and 4 chronic kidney disease (mean estimated glomerular filtration rate of 42.17 mL/min.).

Treatment resulted in a number of significant decreases, Dr. Luño noted. Among those decreases observed were the following:

· blood pressure (158/84 mm Hg before treatment versus 137/74 mm Hg after treatment; P = .000)

· urinary protein excretion (2.29 versus 1.21; P = .03)

· homeostasis model assessment index (6 versus 4.7 mcU/mL x mmol/L; P = .02)

· plasma glucose (99 versus 92 mg/dL; P = .000)

· plasma insulin (23.1 versus 20.9 UI/mL; P = .05) and

· glycated haemoglobin (5.33% versus 4.85%; P = .002).

Some inflammatory parameters were also reduced with olmesartan treatment, including fibrinogen, C-reactive protein and interleukin-6. There were no significant differences in body mass index, triglycerides, or cholesterol (either high-density lipoprotein or low-density lipoprotein cholesterol) after olmesartan treatment.

Study participants were nondiabetic and were never treated previously with renin-angiotensin-system blocking drugs. Baseline data were compared with data obtained from 25 healthy individuals of similar age (approximately 70 years old) and normal renal function (98.33 mL/min), who served as a control group.

Compared with controls, patients with chronic kidney disease presented at baseline with significantly higher blood pressure, as well as higher triglyceride levels and lower high-density lipoprotein levels, higher insulin levels and a higher mean homeostasis model assessment index.

The prevalence of metabolic syndrome in the patients with chronic kidney disease was 44% at baseline.

[Presentation title: Olmesartan Improves Insulin Resistance in Chronic Kidney Disease Patients. Abstract 960]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.